Human papillomavirus biology and cervical neoplasia: Implications for diagnostic criteria and testing

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 8, 2003, Pages 935-939

  Stoler, Mark H ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; TUMOR MARKER; VIRUS DNA; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; VIRUS PROTEIN;

CANCER RISK; CARCINOGENESIS; CELL ULTRASTRUCTURE; CONDYLOMA; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DNA SEQUENCE; GENE EXPRESSION; HUMAN; NONHUMAN; ONCOGENE; ONCOGENE NEU; RISK FACTOR; SEQUENCE ANALYSIS; SEXUALLY TRANSMITTED DISEASE; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX EPITHELIUM; UTERINE CERVIX TUMOR; WART VIRUS; ARTICLE; BIOLOGICAL MODEL; CLASSIFICATION; DIAGNOSTIC PROCEDURE; DNA PROBE; FEMALE; GENETICS; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY; SPECIES DIFFERENCE; VIROLOGY; VIRUS CELL TRANSFORMATION; VIRUS GENE; VIRUS INFECTION;

BIOLOGICAL MARKERS; CELL TRANSFORMATION, VIRAL; DNA PROBES, HPV; DNA, VIRAL; FEMALE; GENES, VIRAL; HUMANS; MODELS, GENETIC; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; SPECIES SPECIFICITY; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL STRUCTURAL PROTEINS;

EID: 0043176279     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Stoler MH. Advances in cervical screening technology. Mod Pathol. 2000; 13:275-284.
2. Shah KV, Howley PM. Papillomaviruses. In: Field BN, Knipe DM, eds. Field's Virology. 3rd ed. New York, NY: Raven Press; 1995:980-998.
3. Howley PM. Papillomaviruses and their replication. In: Field BN, Knipe DM, eds. Field's Virology. 3rd ed. New York, NY: Raven Press; 1995:947-979.
4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-350.
5. de Villiers EM. Human papillomavirus: introduction. Semin Cancer Biol. 1999;9:377.
6. Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer. 1995;76(10 suppl):1888-1901.
7. Schiffman MH. Epidemiology of cervical human papillomavirus infections. Curr Top Microbiol Immunol. 1994;186:55-81.
8. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis. 2001;183:8-15.
9. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998; 338:423-428.
10. Koss LG, Durfee GR. Unusual patterns of squamous epithelium of the uterine cervix: cytologic and pathologic study of koilocytotic atypia. Ann N Y Acad Sci. 1956;63:1245-1261.
11. Meisels A. The story of a cell: The George N. Papanicolaou Award lecture. Acta Cytol. 1983;27:584-596.
12. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group [see comments]. J Natl Cancer Inst. 1995;87:796-802.
13. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
14. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992;79:328-337.
15. Richart RM, Masood S, Syrjanen KJ, et al. Human papillomavirus. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial. Acta Cytol. 1998;42:50-58.
16. Stoler MH, Mills SE, Gersell DJ, Walker AN. Small-cell neuroendocrine carcinoma of the cervix: a human papillomavirus type 18-associated cancer. Am J Surg Pathol. 1991;15:28-32.
17. The ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst. 2000;92:397-402.
18. Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol. 1992;23:117-228.
19. Cullen AP, Reid R, Campion M, Lorincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol. 1991;65:606-612.
20. Stoler MH. Human papillomavirus and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol. 2000;19:16-28.
21. Stoler MH. New Bethesda terminology and evidence-based management guidelines for cervical cytology findings. JAMA. 2002;287:2140-2141.
22. Henson D, Fielding L, Grignon D, et al. College of American Pathologists Conference XXVI on Clinical Relevance of Prognostic Markers in Solid Tumors: summary. Arch Pathol Lab Med. 1995;119:1109-1114.
23. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers [see comments]. J Natl Cancer Inst. 1996;88:1456-1466.
24. Sherman ME, Schiffman MH, Lorincz AT, et al. Toward objective quality assurance in cervical cytopathology: correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol. 1994;102: 182-187.
25. Stoler MH. Toward objective quality assurance: the eyes don't have it. Am J Clin Pathol. 2002;117:520-522.
26. Stoler MH, Schiffman M. Inter-observer reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study (ALTS). JAMA. 2001;285:1500-1506.
27. Stoler MH. In situ hybridization: a research technique or routine diagnostic test? Arch Pathol Lab Med. 1993;117:478-481.
28. Quint WG, Scholte G, van Doorn LJ, Kleter B, Smits PH, Lindeman J. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF(10) PCR and HPV genotyping. J Pathol. 2001; 194:51-58.
29. van Doorn LJ, Quint W, Kleter B, et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol. 2002;40:979-983.
30. von Knebel Doeberitz M. New molecular tools for efficient screening of cervical cancer. Dis Markers. 2001;17:123-128.
31. Jelen I, Valente PT, Gautreaux L, Clark GM. Deoxyribonucleic acid ploidy and S-phase fraction are not significant prognostic factors for patients with cervical cancer. Am J Obstet Gynecol. 1994;171:1511-1516; discussion, 16-18.
32. Kenter GG, Cornelisse CJ, Aartsen EJ, et al. DNA ploidy level as prognostic factor in low stage carcinoma of the uterine cervix. Gynecol Oncol. 1990;39: 181-185.
33. Lutgens LC, Schutte B, de Jong JM, Thunnissen FB. DNA content as prognostic factor in cervix carcinoma stage IB-III treated with radiotherapy. Gynecol Oncol. 1994;54:275-281.
34. Nguyen HN, Sevin BU, Averette HE, et al. The role of DNA index as a prognostic factor in early cervical carcinoma. Gynecol Oncol. 1993;50:54-59.
35. Cina SJ, Richardson MS, Austin RM, Kurman RJ. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix. Mod Pathol. 1997;10:176-180.
36. Maeda MY, Simoes M, Wakamatsu A, et al. Relevance of the rates of PCNA, Ki-67 and p53 expression according to the epithelial compartment in cervical lesions. Pathologica. 2001;93:189-195.
37. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol. 2001;25:884-891.
38. Bar JK, Harlozinska A, Sedlaczek P, Kasiak J, Markowska J. Relations between the expression of p53, c-erbB-2, Ki-67 and HPV infection in cervical carcinomas and cervical dysplasias. Anticancer Res. 2001;21:1001-1006.
39. Geng L, Connolly DC, Isacson C, Ronnett BM, Cho KR. Atypical immature metaplasia (AIM) of the cervix: is it related to high-grade squamous intraepithelial lesion (HSIL)? Hum Pathol. 1999;30:345-351.
40. Resnick M, Lester S, Tate JE, Sheets EE, Sparks C, Crum CP. Viral and histopathologic correlates of MN and MIB-1 expression in cervical intraepithelial neoplasia [see comments]. Hum Pathol. 1996;27:234-239.
41. Konishi I, Fujii S, Nonogaki H, Nanbu Y, Iwai T, Mori T. Immunohistochemical analysis of estrogen receptors, progesterone receptors, Ki-67 antigen, and human papillomavirus DNA in normal and neoplastic epithelium of the uterine cervix. Cancer. 1991;68:1340-1350.
42. Cardillo MR, Stamp GW, Pignatelli MN, Lalani EN. Immunohistochemical analysis of p53 oncoprotein and proliferating cell nuclear antigen (PCNA) in the cervix uteri. Eur J Gynaecol Oncol. 1993;14:484-490.
43. Dellas A, Schultheiss E, Almendral AC, Torhorst J, Gudat F. Assessment of EGFR and TGF-alpha expression in relationship to HPV status and Ki-67 distribution in cervical intraepithelial neoplasms. Int J Cancer. 1996;69:165-169.
44. Dellas A, Schultheiss E, Holzgreve W, Oberholzer M, Torhorst J, Gudat F. Investigation of the Bcl-2 and c-myc expression in relationship to the Ki-67 labelling index in cervical intraepithelial neoplasia. Int J Gynecol Pathol. 1997;16: 212-218.
45. Tjalma WA, Weyler JJ, Bogers JJ, et al. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol. 2001;97:223-230.
46. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276-284.